Navigation Links
GM canola ban "disappointing"
Date:2/8/2008

The South Australian Governments decision to extend a moratorium on genetically modified canola is not supported by scientific evidence and may send the wrong message about the role of science in agriculture, experts in plant science and technology say.

The experts based at the Australian Centre for Plant Functional Genomics (ACPFG) at the University of Adelaides Waite Campus say Australian farmers should be provided with every technology, whether GM or not, to help overcome the ravaging effects of national problems such as drought and salinity.

The State Governments decision is disappointing says University of Adelaide Federation Fellow Professor Mark Tester, and the Director of the Universitys Waite Campus, Professor Geoff Fincher, both based at the ACPFG.

This decision is not supported by the extensive scientific evidence that has been accumulated over 10 years in many countries around the world and could send negative signals to the community about the potential benefits of science and the application of new technologies, Professor Tester says.

Currently the Australian Federal Government, through the Office of the Gene Technology Regulator, monitors all genetic modification research on a case-by-case basis, under stringent control guidelines.

Most cases show that in recent years, countries with access to genetically modified crops have reaped environmental benefits, particularly in the developing world. There is little doubt in the scientific community that genetic modification is part of a sustainable farming future, says the Director of the University of Adelaides Waite Campus and Deputy CEO of the ACPFG, Professor Geoff Fincher.

We need to ensure that the community is properly informed of the issues related to the application of this technology. We hope that South Australian farmers will be given the opportunity to use this technology in the future for the benefit of farmers, consumers and the environment, Professor Tester says.


'/>"/>

Contact: Mark Tester
mark.tester@acpfg.com.au
61-883-037-159
University of Adelaide
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: